No Data
Emerging Markets outlook: Attention may turn towards lightly traded ultra-low-priced stocks and biotech-related stocks.
■ Emerging Markets are left out of the investment choices. This week, Emerging Markets declined. During the same period, the Nikkei average fell by -1.95%, while the Growth Market Index fell by -2.67%, and the Growth Market 250 Index fell by -3.09%, indicating that Emerging Markets were relatively weaker. As attention turns to the central bank meetings in Japan and the United States, reports of Nissan <7201> and Honda <7267> beginning discussions on a management integration have redirected interest towards auto stocks and Auto Parts suppliers in the Main Board, leaving Emerging Markets out of the investment picture.
The Tokyo Stock Exchange Growth Index continues to decline, with lackluster price movements ahead of the Japan and US central bank meetings.
Tokyo Stock Exchange Growth Market Index 814.89 -2.43 / Volume 0.2 billion 14.75 million shares / Trading value 145.5 billion yen Tokyo Stock Exchange Growth Market 250 Index 635.44 -2.83 / Volume 0.1 billion 5.09 million shares / Trading value 97.2 billion yen Today's growth market saw a continued decline in both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index, with 187 rising stocks, 363 declining stocks, and 45 unchanged. Today's growth market showed a soft trend. On the previous day, October 16 in the USA.
Volume change rate ranking (9 AM slot) - DWTI, Asiro, ETC are ranked.
In the Volume change rate ranking, by comparing the average Volume of the last 5 days with the Volume on the day of distribution, it is possible to understand the trends in stock selection and the interests of market participants. ■ Top Volume change rates [As of December 16, 9:35] (Comparison of the average Volume of the last 5 days) Stock code Stock name Volume Average Volume over 5 days Volume change rate Stock price change rate <2624> iF225 Year 464086107185.0 8264.1% 0.0025% <7378> Ashi
OncoTherapy Science 1H Loss Y545.00M Vs Loss Y710.00M
OncoTherapy Science: Confirmation letter
OncoTherapy Science: Interim report - 24th term (2024/04/01 - 2025/03/31)
No Data